US 12,377,072 B2
Modulators of GTPases and their use
Angela Wandinger-Ness, Albuquerque, NM (US); Laurie Hudson, Albuquerque, NM (US); Larry Sklar, Albuquerque, NM (US); Zurab Surviladze, Albuquerque, NM (US); and Tudor Oprea, Albuquerque, NM (US)
Assigned to UNM Rainforest Innovations, Albuquerque, NM (US)
Filed by UNM Rainforest Innovations, Albuquerque, NM (US)
Filed on Apr. 24, 2023, as Appl. No. 18/138,306.
Application 18/138,306 is a continuation of application No. 17/095,399, filed on Nov. 11, 2020, granted, now 11,672,779.
Application 17/095,399 is a continuation of application No. 15/445,413, filed on Feb. 28, 2017, granted, now 10,857,130.
Application 15/445,413 is a continuation of application No. 14/813,874, filed on Jul. 30, 2015, abandoned.
Application 14/813,874 is a continuation of application No. 13/161,766, filed on Jun. 16, 2011, granted, now 9,125,899.
Claims priority of provisional application 61/397,864, filed on Jun. 17, 2010.
Prior Publication US 2023/0404977 A1, Dec. 21, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/407 (2006.01); A61K 31/403 (2006.01); A61K 31/415 (2006.01); A61K 45/06 (2006.01); C07D 231/06 (2006.01); C12Q 1/6886 (2018.01); G01N 33/573 (2006.01)
CPC A61K 31/407 (2013.01) [A61K 31/403 (2013.01); A61K 31/415 (2013.01); A61K 45/06 (2013.01); C07D 231/06 (2013.01); C12Q 1/6886 (2013.01); G01N 33/573 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); Y02A 50/30 (2018.01)] 8 Claims
OG exemplary drawing
 
1. A method of modulating GTPase in a human patient with ovarian cancer, the method comprising administering to said patient an anti-cancer effective amount of a composition comprising ketorolac, or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier, additive or excipient, wherein the ketorolac consists of an effective amount of R-ketorolac.